Frank Vinluan from MedCity News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation		Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - 27 days ago Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug - 27 days ago FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection - 28 days ago Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD - 29 days ago Anne Wojcicki Had a Fully Financed Plan to Take 23andMe Private. Then It Fell Apart. - about 1 month ago Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases - about 1 month ago Novo Nordisk Launches Lower-Cost Wegovy, Following Eli Lilly Into Direct-to-Patient Sales - about 2 months ago VC Firm Sofinnova Partners Pulls In €1.2B to Deploy Across Life Sciences Investments - about 2 months ago AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic - about 2 months ago Praxis Presses Forward in Essential Tremor Despite Futility Finding From Trial Observers - about 2 months ago BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - about 2 months ago Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M - about 2 months ago Merck Is Embracing AI, But ‘We Always Have a Human in the Loop,’ Exec Says - 2 months ago Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma - 2 months ago Aardvark Therapeutics’ Pursuit of New Obesity Target Adds $94M in IPO Cash - 2 months ago FDA Approval of Drug for Rare Tumors Enables SpringWorks to Challenge AstraZeneca - 2 months ago Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots - 2 months ago Pliant Therapeutics Presses Pause on Clinical Trial for Lung Disorder Drug - 2 months ago Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline - 2 months ago Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma - 3 months ago Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval - 3 months ago Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects - 3 months ago Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval - 3 months ago Pfizer Drug Hits Goals of Colorectal Cancer Study, Clearing Way to Seek Full FDA Approval - 3 months ago Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - 3 months ago Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds - 3 months ago FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer - 3 months ago Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation - 3 months ago At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected - 3 months ago J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies - 3 months ago Galapagos Keeps Focus on Cancer Cell Therapy, Spins Out Rest of Biz Into NewCo Backed by €2.4B - 4 months ago Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - 4 months ago Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health - 4 months ago A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly - 4 months ago FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions - 4 months ago Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing - 4 months ago Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data - 4 months ago Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug - 4 months ago The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - 4 months ago Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies - 4 months ago Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea - 4 months ago Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds - 4 months ago Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug - 4 months ago Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - 4 months ago Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site - 4 months ago ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - 4 months ago AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots - 4 months ago Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - 4 months ago GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH - 5 months ago Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug - 5 months ago